Cahill Represents Lead Arranger in $575 Million Revolving Credit Facility for Halozyme Therapeutics, Inc.

August 18, 2022

Cahill represented the Lead Arranger in connection with an amendment to Halozyme Therapeutics, Inc.’s credit agreement to increase the revolving credit facility by $225,000,000 to $575,000,000. Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving patient experience and outcomes.